FDA issues warning letter after GLP-1 manufacturer refuses inspectors access

Wednesday, April 22, 2026 – Thursday, April 23 - New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.







